KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy.-Reference-Cited by-同舟云学术

KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:TPS4572-TPS4572
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Bajorin Dean F.¹,Plimack Elizabeth R.²,Siefker-Radtke Arlene O.³,Choueiri Toni K.⁴,De Wit Ronald⁵,Sonpavde Guru⁶,Gipson Adrianna⁷,Brown Holly⁷,Mai Yabing⁷,Pang Lei⁷,Perini Rodolfo F.⁷,Bellmunt Joaquim⁸

Affiliation:

1. Memorial Sloan Kettering Cancer Center, New York, NY

2. Director, Genitourinary Clinical Research Fox Chase Cancer Center, Philadelphia, PA

3. The University of Texas MD Anderson Cancer Center, Houston, TX

4. Dana-Farber Cancer Institute, Boston, MA

5. Erasmus MC Cancer Institute, Rotterdam, Netherlands

6. Director, Urologic Oncology Associate Professor of Medicine University of Alabama at Birmingham (UAB) Comprehensive Cancer Center, Birmingham, AL

7. Merck & Co., Inc., Kenilworth, NJ

8. Director, Bladder Cancer Center Dana-Farber Cancer Institute Dana-Farber/Brigham and Women's Cancer Center Associated Professor, Harvard Medical School, Boston, MA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2015.33.15_suppl.tps4572

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Introduction on Cancer Immunotherapy;Handbook of Cancer and Immunology;2023

2. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers;Clinical Science;2019-01

3. Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States;Bladder Cancer;2018-04-26

4. An FGFR 3/ MYC positive feedback loop provides new opportunities for targeted therapies in bladder cancers;EMBO Molecular Medicine;2018-02-20

5. Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors;Cancers;2018-01-25